Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Ochre Bio raises $30 million for RNA-based liver disease therapies

by Gina Vitale
October 15, 2022 | A version of this story appeared in Volume 100, Issue 37

 

Two casually dressed and smiling men.
Credit: Business Wire
Ochre Bio cofounders Quin Wills (left) and Jack O'Meara

Ochre Bio has raised $30 million in series A funding to develop RNA therapies for chronic liver diseases. The UK start-up creates potential RNA therapies to reprogram the liver and tests them on discarded donor livers, which can be kept alive outside the body for multiple days. Ochre says it will use the funding to translate its research into drug candidates. It expects to move candidates to clinical development in 2024.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.